Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
07 11월 2019 - 3:15AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that the company will participate in
the Society for Immunotherapy of Cancer (SITC) Annual Meeting in
National Harbor, MD, November 7-10, including poster presentations
on November 8th and 9th.
The company will showcase ImmunoID NeXT™, the first platform to
enable comprehensive analysis of both a tumor and its immune
microenvironment from a single sample. ImmunoID NeXT™ can be used
to investigate the key tumor- and immune-related areas of cancer
biology, consolidating multiple oncology biomarker assays into one
and maximizing the biological information that can be generated
from a precious tumor specimen.
Following is a list of abstracts that will be presented at the
meeting.
Scientific Poster Presentations
Poster Number & Category
Title & Presenter
Day & Time
Location
P77
Biomarkers, Immune Monitoring, and Novel
Technologies
Comprehensive profiling of tumor-immune
interaction in anti-PD-1 treated melanoma patients reveals
subject-specific tumor escape mechanisms
Presenter: Charles Abbott, Ph.D.
November 8: 12:30 PM – 2:00 PM and 6:30 PM
– 8:00 PM
Poster Hall: Prince George AB
P72
Biomarkers, Immune Monitoring, and Novel
Technologies
Comprehensive and accurate prediction
of presented neoantigens using ImmunoID NeXT and advanced machine
learning algorithms
Presenters: Dattatreya Mellacheruvu, Ph.D.
and Rachel Pyke, Ph.D.
November 9: 12:35 PM – 2:05 PM and 6:30 PM
– 8:00 PM
Poster Hall: Prince George AB
P96
Biomarkers, Immune Monitoring, and Novel
Technologies
T-cell receptor alpha and beta
repertoire profiling using an augmented transcriptome
Presenter: Eric Levy, Ph.D.
November 9: 12:35 PM – 2:05 PM and 7:00 PM
– 8:30 PM
Poster Hall: Prince George AB
Personalis will also be exhibiting during the conference (Booth
# 431). Representatives will be available to answer questions about
the company’s cancer immunogenomics services.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191106005817/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024